Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-06-23
DOI
10.3389/fimmu.2020.01295
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials
- (2020) Jackson G. Egen et al. IMMUNITY
- Neoadjuvant checkpoint blockade for cancer immunotherapy
- (2020) Suzanne L. Topalian et al. SCIENCE
- Resistance to Checkpoint Inhibition in Cancer Immunotherapy
- (2020) Luisa Barrueto et al. Translational Oncology
- Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors
- (2020) Ombretta Melaiu et al. Frontiers in Immunology
- Tumor Microenvironment-Associated Extracellular Matrix Components Regulate NK Cell Function
- (2020) Gustavo Rodrigues Rossi et al. Frontiers in Immunology
- NK Cell Priming From Endogenous Homeostatic Signals Is Modulated by CIS
- (2020) Rebecca B. Delconte et al. Frontiers in Immunology
- Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy
- (2020) Rachael M. Zemek et al. Frontiers in Immunology
- Unleashing Natural Killer Cells in the Tumor Microenvironment–The Next Generation of Immunotherapy?
- (2020) Aviad Ben-Shmuel et al. Frontiers in Immunology
- The NKG2A immune checkpoint — a new direction in cancer immunotherapy
- (2019) Benjamin C. Creelan et al. Nature Reviews Clinical Oncology
- Targeting natural killer cells in solid tumors
- (2019) Guillaume Habif et al. Cellular & Molecular Immunology
- Human NK cells: surface receptors, inhibitory checkpoints, and translational applications
- (2019) Simona Sivori et al. Cellular & Molecular Immunology
- Expression analysis and significance of PD-1, LAG-3 and TIM-3 in human non-small cell lung cancer using spatially-resolved and multiparametric single-cell analysis.
- (2019) Ila J Datar et al. CLINICAL CANCER RESEARCH
- Transforming Growth Factor-β Signaling in Immunity and Cancer
- (2019) Eduard Batlle et al. IMMUNITY
- Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells
- (2019) Takahiro Kamiya et al. JOURNAL OF CLINICAL INVESTIGATION
- Setting traps for NKG2A gives NK cell immunotherapy a fighting chance
- (2019) Frank Cichocki et al. JOURNAL OF CLINICAL INVESTIGATION
- TNF-α-induced Tim-3 expression marks the dysfunction of infiltrating natural killer cells in human esophageal cancer
- (2019) Yujia Zheng et al. Journal of Translational Medicine
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
- (2019) Brian I Rini et al. LANCET
- The role of NK cells and CD39 in the immunological control of tumor metastases
- (2019) Haiyan Zhang et al. OncoImmunology
- Imbalance of Genes Encoding Natural Killer Immunoglobulin-like Receptors and Human Leukocyte Antigen in Patients With Biliary Cancer
- (2019) Martin Cornillet et al. GASTROENTEROLOGY
- Identification of the E3 Ligase TRIM29 as a Critical Checkpoint Regulator of NK Cell Functions
- (2019) Yaling Dou et al. JOURNAL OF IMMUNOLOGY
- Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment
- (2019) Rachael M. Zemek et al. Science Translational Medicine
- Endometrial Tumor Microenvironment Alters Human NK Cell Recruitment, and Resident NK Cell Phenotype and Function
- (2019) Clara Degos et al. Frontiers in Immunology
- What Defines NK Cell Functional Fate: Phenotype or Metabolism?
- (2019) Sophie M. Poznanski et al. Frontiers in Immunology
- Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression
- (2019) Antonino Bruno et al. Frontiers in Immunology
- Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation
- (2019) Daniela Pende et al. Frontiers in Immunology
- Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function
- (2019) Selena Vigano et al. Frontiers in Immunology
- Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity
- (2019) Barbara Seliger Frontiers in Immunology
- PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
- (2019) Silvia Pesce et al. Frontiers in Immunology
- Chronic stimulation drives human NK cell dysfunction and epigenetic reprograming
- (2019) Aimee Merino et al. JOURNAL OF CLINICAL INVESTIGATION
- IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial
- (2019) Martine Bagot et al. LANCET ONCOLOGY
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- NK Cell Dysfunction and Checkpoint Immunotherapy
- (2019) Jiacheng Bi et al. Frontiers in Immunology
- NK Cell Metabolism and Tumor Microenvironment
- (2019) Iñigo Terrén et al. Frontiers in Immunology
- Immunological memory: ILC1s come into view
- (2019) Yawen Chen et al. Cellular & Molecular Immunology
- Combined NK Cell Therapy and Radiation Therapy Exhibit Long-Term Therapeutic and Antimetastatic Effects in a Human Triple Negative Breast Cancer Model
- (2019) Kyung Won Kim et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy
- (2019) Haoyu Sun et al. Frontiers in Immunology
- Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer
- (2019) Hauke Stamm et al. OncoImmunology
- Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells
- (2019) Beatris Mastelic-Gavillet et al. Journal for ImmunoTherapy of Cancer
- Monalizumab: inhibiting the novel immune checkpoint NKG2A
- (2019) Thorbald van Hall et al. Journal for ImmunoTherapy of Cancer
- Tim-3 hampers tumor surveillance of liver resident and conventional NK cells by disrupting PI3K signaling
- (2019) Siyu Tan et al. CANCER RESEARCH
- Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation
- (2018) Robert L. Ferris et al. CANCER TREATMENT REVIEWS
- NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control
- (2018) Jan P. Böttcher et al. CELL
- Dysfunction of Natural Killer Cells by FBP1-Induced Inhibition of Glycolysis during Lung Cancer Progression
- (2018) Jingjing Cong et al. Cell Metabolism
- Mechanistic insights into cancer immunity and immunotherapy
- (2018) Weiping Zou Cellular & Molecular Immunology
- Activated pancreatic stellate cells inhibit NK cell function in the human pancreatic cancer microenvironment
- (2018) Qiang Huang et al. Cellular & Molecular Immunology
- IDO1 in cancer: a Gemini of immune checkpoints
- (2018) Lijie Zhai et al. Cellular & Molecular Immunology
- Predictive immune biomarkers: an unattainable chimera?
- (2018) Anna Maria Trotta et al. Cellular & Molecular Immunology
- TLR-mediated metabolic reprogramming in the tumor microenvironment: potential novel strategies for cancer immunotherapy
- (2018) Lan Huang et al. Cellular & Molecular Immunology
- The cellular metabolic landscape in the tumor milieu regulates the activity of myeloid infiltrates
- (2018) Eslam Mohamed et al. Cellular & Molecular Immunology
- Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment
- (2018) Ganjun Yu et al. Cellular & Molecular Immunology
- Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy
- (2018) Xiaolei Li et al. Cellular & Molecular Immunology
- The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation
- (2018) Wenwen Xu et al. Cellular & Molecular Immunology
- Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor–Mediated Natural Killer Cell Function
- (2018) Andrew Stiff et al. CLINICAL CANCER RESEARCH
- IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma
- (2018) Carrie Van Der Weyden et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer
- (2018) Xiaoling Xu et al. INTERNATIONAL JOURNAL OF CANCER
- Canonical TGF-β Signaling Pathway Represses Human NK Cell Metabolism
- (2018) Vanessa Zaiatz-Bittencourt et al. JOURNAL OF IMMUNOLOGY
- A2AAdenosine Receptor Gene Deletion or Synthetic A2AAntagonist Liberate Tumor-Reactive CD8+T Cells from Tumor-Induced Immunosuppression
- (2018) Jorgen Kjaergaard et al. JOURNAL OF IMMUNOLOGY
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
- (2018) Carsten Denkert et al. LANCET ONCOLOGY
- Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
- (2018) Qing Zhang et al. NATURE IMMUNOLOGY
- A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments
- (2018) Kevin C. Barry et al. NATURE MEDICINE
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC
- (2018) Yayi He et al. Drug Design Development and Therapy
- IL21 Therapy Combined with PD-1 and Tim-3 Blockade Provides Enhanced NK Cell Antitumor Activity against MHC Class I–Deficient Tumors
- (2018) Hyungseok Seo et al. Cancer Immunology Research
- Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells
- (2018) Felix S. Lichtenegger et al. Frontiers in Immunology
- Coming of Age: CD96 Emerges as Modulator of Immune Responses
- (2018) Hristo Georgiev et al. Frontiers in Immunology
- Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
- (2018) Rebekka Weber et al. Frontiers in Immunology
- TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
- (2018) Alice L. Hung et al. OncoImmunology
- TIGIT: a novel immunotherapy target moving from bench to bedside
- (2018) Benjamin L. Solomon et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The functional potency of natural killer cells in response to IL-2/IL-15/IL-21 stimulation is limited by a concurrent upregulation of Tim-3 in bladder cancer
- (2018) Wei Zhang et al. EXPERIMENTAL CELL RESEARCH
- Stromal biology and therapy in pancreatic cancer: ready for clinical translation?
- (2018) Albrecht Neesse et al. GUT
- Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
- (2018) Joy Hsu et al. JOURNAL OF CLINICAL INVESTIGATION
- The hallmarks of successful anticancer immunotherapy
- (2018) Lorenzo Galluzzi et al. Science Translational Medicine
- Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells
- (2018) Nayoung Kim et al. Frontiers in Immunology
- Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
- (2018) Pascale André et al. CELL
- Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
- (2018) Jun Wang et al. CELL
- Targeting PVR (CD155) and its receptors in anti-tumor therapy
- (2018) Paola Kučan Brlić et al. Cellular & Molecular Immunology
- Warm up, cool down, and tearing apart in NK cell memory
- (2018) Lawrence Shih-Hsin Wu et al. Cellular & Molecular Immunology
- Human CD96 correlates to NK cell exhaustion and predicts the prognosis of human hepatocellular carcinoma
- (2018) Haoyu Sun et al. HEPATOLOGY
- Lactate-mediated acidification of tumor microenvironment induces apoptosis of liver-resident NK cells in colorectal liver metastasis
- (2018) Cathal Harmon et al. Cancer Immunology Research
- PD-L1 Mediates Dysfunction in Activated PD-1+ NK Cells in Head and Neck Cancer Patients
- (2018) Fernando Concha-Benavente et al. Cancer Immunology Research
- Tumor Microenvironment-Induced Immunometabolic Reprogramming of Natural Killer Cells
- (2018) Andrea M. Chambers et al. Frontiers in Immunology
- Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8+ T Cells
- (2018) Xiu-Man Zhou et al. Frontiers in Immunology
- Tuning inflammation and immunity by the negative regulators IL-1R2 and IL-1R8
- (2017) Martina Molgora et al. IMMUNOLOGICAL REVIEWS
- The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets
- (2017) Bertrand Allard et al. IMMUNOLOGICAL REVIEWS
- TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy
- (2017) William C. Dougall et al. IMMUNOLOGICAL REVIEWS
- Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization
- (2017) Silvia Pesce et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Blockade of adenosine A2A receptor enhances CD8+ T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma
- (2017) Si-Rui Ma et al. Molecular Cancer
- IL-1R8 is a checkpoint in NK cells regulating anti-tumour and anti-viral activity
- (2017) Martina Molgora et al. NATURE
- Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers
- (2017) Y Liu et al. ONCOGENE
- IL-21-mediated reversal of NK cell exhaustion facilitates anti-tumour immunity in MHC class I-deficient tumours
- (2017) Hyungseok Seo et al. Nature Communications
- Predictors of responses to immune checkpoint blockade in advanced melanoma
- (2017) N. Jacquelot et al. Nature Communications
- Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
- (2017) Scott Gettinger et al. Cancer Discovery
- NK Cell Exhaustion
- (2017) Jiacheng Bi et al. Frontiers in Immunology
- Coinhibitory Pathways in Immunotherapy for Cancer
- (2016) Susanne H. Baumeister et al. Annual Review of Immunology
- Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses
- (2016) Arabella Young et al. CANCER CELL
- Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT
- (2016) Srinivas Malladi et al. CELL
- Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy
- (2016) S. J. Blake et al. CLINICAL CANCER RESEARCH
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- CIS is a potent checkpoint in NK cell–mediated tumor immunity
- (2016) Rebecca B Delconte et al. NATURE IMMUNOLOGY
- TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway
- (2016) Sébastien Viel et al. Science Signaling
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy
- (2016) S. J. Blake et al. Cancer Discovery
- Neutrophils Suppress Intraluminal NK Cell-Mediated Tumor Cell Clearance and Enhance Extravasation of Disseminated Carcinoma Cells
- (2016) A. Spiegel et al. Cancer Discovery
- Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors
- (2016) Ameet K. Mishra et al. Oncotarget
- PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma
- (2016) Asma Beldi-Ferchiou et al. Oncotarget
- TGF-β inhibits the activation and functions of NK cells by repressing the mTOR pathway
- (2016) Sébastien Viel et al. Science Signaling
- High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer
- (2016) Cheng Sun et al. OncoImmunology
- Targeting CD73 in the tumor microenvironment with MEDI9447
- (2016) Carl M. Hay et al. OncoImmunology
- Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia
- (2016) Emily M. McWilliams et al. OncoImmunology
- Current clinical trials testing the combination of immunotherapy with radiotherapy
- (2016) Josephine Kang et al. Journal for ImmunoTherapy of Cancer
- A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma
- (2015) D. M. Benson et al. CLINICAL CANCER RESEARCH
- Natural Killer Cell Memory
- (2015) Timothy E. O’Sullivan et al. IMMUNITY
- The Clinical Significance of Abnormal Tim-3 Expression on NK Cells from Patients with Gastric Cancer
- (2015) Zhenxin Wang et al. IMMUNOLOGICAL INVESTIGATIONS
- Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma
- (2015) Liyun Xu et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients
- (2015) Joe-Marc Chauvin et al. JOURNAL OF CLINICAL INVESTIGATION
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Critical Role of Tumor Microenvironment in Shaping NK Cell Functions: Implication of Hypoxic Stress
- (2015) Meriem Hasmim et al. Frontiers in Immunology
- Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis
- (2015) Emilia Andersson et al. OncoImmunology
- The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
- (2014) Robert J. Johnston et al. CANCER CELL
- NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma
- (2014) Cheng Sun et al. Cellular & Molecular Immunology
- CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
- (2014) Yu-Hwa Huang et al. NATURE
- The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells
- (2014) Magdalena Paolino et al. NATURE
- The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions
- (2014) Christopher J Chan et al. NATURE IMMUNOLOGY
- Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
- (2014) I. P. da Silva et al. Cancer Immunology Research
- Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR
- (2013) Noa Stanietsky et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Anti-Human CD73 Monoclonal Antibody Inhibits Metastasis Formation in Human Breast Cancer by Inducing Clustering and Internalization of CD73 Expressed on the Surface of Cancer Cells
- (2013) M. G. Terp et al. JOURNAL OF IMMUNOLOGY
- Neuroblastoma-Derived TGF- 1 Modulates the Chemokine Receptor Repertoire of Human Resting NK Cells
- (2013) R. Castriconi et al. JOURNAL OF IMMUNOLOGY
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Blockade of A2Areceptors potently suppresses the metastasis of CD73+tumors
- (2013) Paul A. Beavis et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity
- (2012) L. C. Ndhlovu et al. BLOOD
- Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9
- (2012) M. K. Gleason et al. BLOOD
- NK cell MHC class I specific receptors (KIR): from biology to clinical intervention
- (2012) Ariane Thielens et al. CURRENT OPINION IN IMMUNOLOGY
- Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia
- (2011) Q. Zhou et al. BLOOD
- Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor
- (2011) Adam T. Waickman et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Anti-TIM3 Antibody Promotes T Cell IFN- -Mediated Antitumor Immunity and Suppresses Established Tumors
- (2011) S. F. Ngiow et al. CANCER RESEARCH
- CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis
- (2011) J. Stagg et al. CANCER RESEARCH
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- HLA-E/β2 microglobulin overexpression in colorectal cancer is associated with recruitment of inhibitory immune cells and tumor progression
- (2011) Céline Bossard et al. INTERNATIONAL JOURNAL OF CANCER
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients
- (2010) Julien Fourcade et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Extracellular adenosine triphosphate and adenosine in cancer
- (2010) J Stagg et al. ONCOGENE
- Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis
- (2010) J. Stagg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started